HeartBeam, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026, disclosing continued operating losses as the company advances its cardiac monitoring technology development program.

Key Highlights

  • Net loss of $12.749 million for the nine months ended September 30, 2026, compared to $15.713 million in the same period of 2025, according to the filing.
  • Third-quarter net loss of $3.010 million versus $5.255 million in Q3 2025, reflecting reduced research and development spending, the filing disclosed.
  • Research and development expenses totaled $6.816 million for the nine months ended September 30, 2026, down from $10.096 million in the prior-year period.
  • Cash and cash equivalents of $6.065 million as of September 30, 2026, up from $4.380 million at December 31, 2025.
  • Common shares outstanding rose to 57,513,001 at September 30, 2026, from 40,117,404 at December 31, 2025, following stock sales and equity issuances.
  • Accumulated deficit reached $90.037 million as of September 30, 2026, compared to $77.288 million at year-end 2025.
  • Total stockholders' equity of $6.514 million at quarter end, up from $2.603 million at December 31, 2025.

HeartBeam's Q3 2026 Financials Reflect Reduced Spending and New Capital Raises

HeartBeam, Inc. (NASDAQ:BEAT), a Santa Clara, California-based company focused on cardiac monitoring technology, reported a net loss of $3.010 million for the three months ended September 30, 2026, according to the filing. This compares to a net loss of $5.255 million in the third quarter of 2025. The company reported no revenue in either period, as it remains in a development stage, with all operating expenses driven by research and development activity and general and administrative costs.

Research and development expenses for the third quarter of 2026 were $2.118 million, down from $3.278 million in Q3 2025, the filing stated. Selling, general and administrative expenses came in at $1.339 million for the same quarter, compared to $2.012 million a year earlier. For the nine months ended September 30, 2026, total operating expenses were $13.265 million, versus $15.829 million in the comparable 2025 period, reflecting lower spending across both expense categories, the company disclosed.

HeartBeam raised capital during the nine-month period through multiple channels. According to the filing, the company completed a sale of common stock raising net proceeds of $10.265 million from 14,375,000 shares, and an additional $1.515 million net through its at-the-market offering program from 970,467 shares. Stock-based compensation expense of $3.855 million was also recorded over the nine-month period. Total assets stood at $7.872 million as of September 30, 2026, against total liabilities of $1.358 million, leaving total stockholders' equity of $6.514 million. The company carried inventory of $114 thousand and property and equipment, net of $1.516 million on its balance sheet, the filing showed. Net loss per share, basic and diluted, was $0.05 for Q3 2026, compared to $0.15 in Q3 2025.

What Was Disclosed

HeartBeam's 10-Q for the quarter ended September 30, 2026 disclosed operating losses totaling $12.749 million year-to-date, reduced R&D and SG&A spending versus the prior year, capital raises through stock sales, and a quarter-end cash balance of $6.065 million, with 63,312,796 shares outstanding as of November 10, 2026.